Antibody-DM1 conjugates as cancer therapeutics
Author:
- 1 August 2011
- journal article
- review article
- Published by Elsevier in Cancer Letters
- Vol. 307 (2) , 113-118
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- A Molecular and Structural Mechanism for G Protein-mediated Microtubule DestabilizationJournal of Biological Chemistry, 2011
- HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenibBreast Cancer Research and Treatment, 2010
- Maytansinoid-Antibody Conjugates Induce Mitotic Arrest by Suppressing Microtubule Dynamic InstabilityMolecular Cancer Therapeutics, 2010
- Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to MicrotubulesMolecular Cancer Therapeutics, 2010
- Microtubule-binding agents: a dynamic field of cancer therapeuticsNature Reviews Drug Discovery, 2010
- Antibody-Drug Conjugates Designed to Eradicate Tumors with Homogeneous and Heterogeneous Expression of the Target AntigenCancer Research, 2006
- Drug-conjugated monoclonal antibodies for the treatment of cancerCurrent Opinion in Pharmacology, 2005
- Cis-aconityl spacer between daunomycin and macromolecular carriers: A model of pH-sensitive linkage releasing drug from a lysosomotropic conjugateBiochemical and Biophysical Research Communications, 1981
- Maytansine binding to the vinblastine sites of tubulinFEBS Letters, 1977
- Binding of maytansine to rat brain tubulinBiochemical and Biophysical Research Communications, 1976